Pablo Lamelas – Last Thursday June 24th the first SOLACI/SIAC joint guideline was presented at ICBA Instituto Cardiovascular Rounds. Here we present a summary in English with outstanding faculty, an … Continue reading SOLACI/SIAC 2021 Guideline on the use of TAVI vs SAVR in Latin America: Presentation at ICBA Grand Rounds.
by Fernando Botto, MD, MSc During 2020, most research was focused on powerful and modern anti-inflammatory drugs, unfortunately expensive and not widely available for everyone. Colchicine is a cheap and … Continue reading COLCORONA: a challenging viewpoint
Pablo Lamelas – In the last decades multiple trials comparing the efficacy of PCI vs CABG incorporated repeat revascularization in the primary composite outcome, which favoured CABG repeatedly, and frequently … Continue reading Readdressing the validity of Repeat Revascularization outcome in PCI vs CABG trials
Fernando Botto – A general rule dictates “the more the antithombotic effect, the higher the risk of bleeding”. In stable CAD patients beyond 1 year of PCI or without prior … Continue reading NOACs in stable CAD with Atrial Fibrillation: with or without aspirin? The AFIRE trial
Pablo Lamelas – In TCT 2019 Dr Stone published the results of EXCEL trial at 5-years which triggered many controversies in TCT, EACTS, social media, etc. Does this 5-year report … Continue reading EXCEL 5-years: Trial-Based Vs Evidence-Based Medicine
Pablo Lamelas – In TCT 2019 two trials testing different TAVR designs were presented: SCOPE I (ACURATE neo vs Sapien 3) and Portico IDE trial (Portico vs other devices available). … Continue reading New TAVR studies: Weak design not the solution for small trials
Fernando Botto – ESC 2019 hot line sessions delivered us enough evidence to discuss methods and patient-centered decisions. For instance, dual antiplatelet treatment came up with a new trial in … Continue reading THEMIS trial: when significant is not significant
Pablo Lamelas – One of the top surprises from ESC congress 2019 was ISAR-REACT 5 trial, which concluded that in acute coronary syndromes Prasugrel was superior to Ticagrelor for efficacy … Continue reading Ticagrelor vs Prasugrel ISAR-REACT 5: A lesson learned
Pablo Lamelas – Hypertension is the largest responsible of death in the world. Its control and risk reduction is a health priority, specially middle- and low-income countries where risk factor … Continue reading Reducing cardiovascular risk in hypertension – HOPE-4 Trial
Pablo Lamelas – Multiple small randomized trials evaluating the effect of complete revascularization in STEMI suggested that complete revascularization was associated with a marked reduction (50%) in cardiovascular death, as … Continue reading Complete vs Culprit Only Revascularization after STEMI: Why do we need large trials like COMPLETE?
Fernando Botto – Patients with any form of Atrial Fibrillation (AF) having an estimated thromboembolic risk (stroke or systemic embolism) of 1% or more per year should be considered for … Continue reading Oral anticoagulation in Atrial Fibrillation with CHA2DS2-VASc = 1: too much uncertainty?
Pablo Lamelas – In the recent years several randomized trials comparing complete vs culprit-only revascularization were published, in which many of them were ¨positive¨. Then, do we have a definitive … Continue reading Complete vs culprit-only revascularization in STEMI
Pablo Lamelas – In 2016 two large randomized trials testing the role of PCI in left main (LM) disease were published, which seem inconsistent. Are they? what the body of … Continue reading PCI vs CABG for left main disease: EXCEL Vs NOBLE
Pablo Lamelas – AUGUSTUS was the last (until mid 2019) large randomized controlled trial evaluating antithrombotic therapy in patients with atrial fibrillation with indication of oral alticoagulation and concomitant indication … Continue reading Atrial fibrillation and PCI after AUGUSTUS
Pablo Lamelas – At ACC 2019 meeting two large randomized trials of patients at low-risk of Surgical Aortic Valve Replacement (SAVR): PARTNER 3 and EVOLUT low-risk. Here we summarize the … Continue reading TAVR in low-risk patients